Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

26 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Ryzodeg Articles

Blow for Novo Nordisk, as FDA further delays Tresiba and Ryzodeg

11 February 2013

EU approval for Novo Nordisk's Tresiba and Ryzodeg and for Novartis' for Bexsero

22 January 2013

Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis

27 December 2012

Novo Nordisk's Ryzodeg passes regulatory hurdle in Japan; diabetes burden review

3 December 2012

FDA accepts Merck & Co's suvorexant; panel backs Novo's Tresiba and Ryzodeg

9 November 2012

FDA briefing papers for Novo Nordisk's insulin degludec note need to review cardiac risks

6 November 2012

Novo Nordisk says US FDA advisory panel to focus on degludec cardiovascular safety

26 October 2012

EMA panel backing for Novo Nordisk's Tresiba and Ryzodeg: Japanese review

22 October 2012

FDA further delays Novo Nordisk's ultra long-acting insulin products Tresiba and Ryzodeg

19 July 2012

Novo Nordisk starts year with 15% net profits hike

30 April 2012

Showing 1-10 of 10 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS